Cancer Stem Cells Biomarkers in Gastric Carcinogenesis
- 310 Downloads
- 4 Citations
Abstract
Background
Gastric carcinogenesis is a multistep process, involving multiple molecular alterations, including changes in cancer stem cells (CSCs). The present investigation was undertaken to determine whether changes in cancer stem cells could be utilized as a marker of progression of gastric carcinogenesis by examining the expression of gastric CSCs at different stages of carcinogenesis.
Methods
Ninety-three cases with 31 in each group of chronic superficial gastritis (CSG), chronic atrophic gastritis (CAG), or gastric cancer (GC) were analyzed immunohistochemically for proliferating cell nuclear antigen (PCNA) and Bcl-xl as biomarkers of proliferation and apoptosis, respectively, and CD44, CD166, and LGR5 levels by qRT-PCR as markers of gastric CSCs. Additionally, the levels of P53 and phosphorylated form of epidermal growth factor receptor (p-EGFR) were examined.
Results
While the levels of each of these biomarkers were found to be low to moderate in CSG and CAG patients, they were markedly increased in GC patients, in whom co-expression of CD44 with LGR5 and CD166 with p-EGFR was found to be the highest. We have also observed that although the expression of different CSC markers as well as the levels of p-EGFR were increased in precancerous lesions (CSG and CAG), they are further augmented in GC suggesting that they may play a pivotal role in the development and progression of gastric cancer.
Conclusions
Our observations suggest that the progression to gastric carcinogenesis from preneoplastic lesions such as superficial gastritis and chronic atrophic gastritis is associated with induction of CSCs together with increase in cell proliferation and inhibition of apoptosis.
Keywords
Gastric carcinogenesis Cancer stem cells (CSCs) Chronic atrophic gastritis (CAG)Notes
Acknowledgments
The authors thank Dr. Yao Shi and Min M Li for advice and discussion of histopathological diagnoses. The authors also thank Li N Zhang for the statistical analysis.
Conflict of Interest
The authors have no financial disclosures or conflicts of interests to declare.
References
- 1.Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.PubMedGoogle Scholar
- 2.Genta RM. Atrophy and atrophic gastritis: one step beyond the Sydney system. Ital J Gastroenterol Hepatol. 1998;30:S273–5.PubMedGoogle Scholar
- 3.Correa P, Yardley JH. Grading and classification of chronic gastritis: one American response to the Sydney system. Gastroenterology. 1992;102:355–9.PubMedGoogle Scholar
- 4.Lipkin M, Correa P, Mikol YB, et al. Proliferative and antigenic modifications in human epithelial cells in chronic atrophic gastritis. J Natl Cancer Inst. 1985;75:613–9.PubMedGoogle Scholar
- 5.Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget. 2010;1:387–95.PubMedGoogle Scholar
- 6.Sanders MA, Majumdar AP. Colon cancer stem cells: implications in carcinogenesis. Front Biosci. 2011;16:1651–62.CrossRefGoogle Scholar
- 7.Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007;23:675–99.PubMedCrossRefGoogle Scholar
- 8.Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–44.PubMedCrossRefGoogle Scholar
- 9.Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells—old concepts, new insights. Cell Death Differ. 2008;15:947–58.PubMedCrossRefGoogle Scholar
- 10.Al-Hajj M, Wicha MS, Benito-Herandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer. Proc Natl Acad Sci U S A. 2003;100:3983–8.PubMedCrossRefGoogle Scholar
- 11.Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.PubMedCrossRefGoogle Scholar
- 12.Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104:10158–63.PubMedCrossRefGoogle Scholar
- 13.Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–7.PubMedCrossRefGoogle Scholar
- 14.Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104:973–8.PubMedCrossRefGoogle Scholar
- 15.Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27:1006–20.PubMedCrossRefGoogle Scholar
- 16.Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, et al. Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol. 2008;14:6376–81.PubMedCrossRefGoogle Scholar
- 17.Liu YJ, Yan PS, Li J, Jia JF. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol. 2005;11:6601–6.PubMedGoogle Scholar
- 18.Barker N, Huch M, Kujala P, et al. LGR5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. 2010;6:25–36.PubMedCrossRefGoogle Scholar
- 19.Van der Flier LG, Sabates-Bellver J, Oving I, et al. The intestinal Wnt/TCF signature. Gastroenterology. 2007;132:628–32.PubMedCrossRefGoogle Scholar
- 20.Hsu SY, Liang SG, Hsueh AJ. Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region. Mol Endocrinol. 1998;12:1830–45.PubMedCrossRefGoogle Scholar
- 21.Swart GW. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 2002;81:313–21.PubMedCrossRefGoogle Scholar
- 22.Van Kempen LC, Nelissen JM, Degen WG, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)–ALCAM interaction. J Biol Chem. 2001;276:25783–90.PubMedCrossRefGoogle Scholar
- 23.Cayrol R, Wosik K, Berard JL, et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol. 2008;9:137–45.PubMedCrossRefGoogle Scholar
- 24.Masedunskas A, King JA, Tan F, et al. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett. 2006;580:2637–45.PubMedCrossRefGoogle Scholar
- 25.Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 2004;57:1160–4.PubMedCrossRefGoogle Scholar
- 26.Ishigami S, Ueno S, Arigami T, et al. Clinical implication of CD166 expression in gastric cancer. J Surg Oncol. 2011;103:57–61.PubMedCrossRefGoogle Scholar
- 27.Speer AL, Sala FG, Matthews JA, Grikscheit TC. Murine tissue-engineered stomach demonstrates epithelial differentiation. J Surg Res. 2011;171:6–14.PubMedCrossRefGoogle Scholar
- 28.Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev. 2005;24:47–69.PubMedCrossRefGoogle Scholar
- 29.Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol. 2007;39:1416–31.PubMedCrossRefGoogle Scholar
- 30.Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta. 2006;1766:120–39.PubMedGoogle Scholar
- 31.Dougherty U, Sehdev A, Cerda S, et al. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane modal. Clin Cancer Res. 2008;14:2253–62.PubMedCrossRefGoogle Scholar
- 32.Roberts RB, Min L, Wshington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tunorigenesis. Proc Natl Acad Sci U S A. 2002;99:1521–6.PubMedCrossRefGoogle Scholar
- 33.Ye YW, Zhou Y, Yuan L, et al. Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression. Cancer. 2011;117:5304–13.PubMedCrossRefGoogle Scholar
- 34.Radovanovic D, Knezevic M, Canovic D, Acimovic L. Correlation between p53 expression and clinical-pathological characteristics of gastric cancer. Vojnosanit Pregl. 2011;68:832–6.PubMedCrossRefGoogle Scholar
- 35.Ran ZH, Xu Q, Tong JL, Xiao SD. Apoptotic effect of epigallocatechin-3-gallated on the human gastric cancer cell line MKN 45 via activation of the mitochondrial pathway. World J Gastroenterol. 2007;13:4255–9.PubMedGoogle Scholar